MedTrace Logo

New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer

NCT05117177 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2024-09-19

No results posted yet for this study

Summary

A2A-004 is a three-part multicenter, open-label, Phase I clinical trial intended to evaluate the safety and tolerability, and the pharmacokinetics (PK) and food effect of new formulations of inupadenant (formerly known as EOS100850), in participants with advanced solid tumors.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

Inupadenant

Oral administration

DRUG

Inupadenant

Oral administration

DRUG

Inupadenant

Oral administration

Sponsors & Collaborators

  • iTeos Belgium SA

    collaborator INDUSTRY

  • iTeos Therapeutics

    lead INDUSTRY

Principal Investigators

  • Iteos Clinical Trials · iTeos Belgium SA

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2024-05-09
Completion
2024-05-09
FDA Drug
Yes

Countries

  • Belgium
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05117177 on ClinicalTrials.gov